A Novel Cardiac Bio-marker: ST2: a Review

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2013 Dec 17

PMID 24335613

Citations 57

Authors

Marco Matteo Ciccone

Francesca Cortese

Michele Gesualdo

Roberta Riccardi

Dalia Di Nunzio

Michele Moncelli

Massimo Iacoviello

Pietro Scicchitano

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVD) are the major cause of death worldwide. The identification of markers able to detect the early stages of such diseases and/or their progression is fundamental in order to adopt the best actions in order to reduce the worsening of clinical condition. Brain natriuretic peptide (BNP) and NT-proBNP are the best known markers of heart failure (HF), while troponins ameliorated the diagnosis of acute and chronic coronary artery diseases. Nevertheless, many limitations reduce their accuracy. Physicians have tried to develop further detectable molecules in order to improve the detection of the early moments of CVD and prevent their development. Soluble ST2 (suppression of tumorigenicity 2) is a blood protein confirmed to act as a decoy receptor for interleukin-33. It seems to be markedly induced in mechanically overloaded cardiac myocytes. Thus, HF onset or worsening of a previous chronic HF status, myocardial infarct able to induce scars that make the myocardium unable to stretch well, etc, are all conditions that could be detected by measuring blood levels of soluble ST2. The aim of this review is to explore the possible role of ST2 derived-protein as an early marker of cardiovascular diseases, above all in heart failure and ischemic heart diseases.

Citing Articles

Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial.

Monzo L, Kobayashi M, Ferreira J, Lamiral Z, Delles C, Clark A Cardiovasc Diabetol. 2025; 24(1):111.

PMID: 40057728 PMC: 11890510. DOI: 10.1186/s12933-025-02609-8.

Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.

Wittczak A, Mazurek-Kula A, Banach M, Piotrowski G, Bielecka-Dabrowa A J Clin Med. 2025; 14(2).

PMID: 39860501 PMC: 11765985. DOI: 10.3390/jcm14020496.

Fucoidan Attenuates Cardiac Remodeling by Inhibiting Galectin-3 Secretion, Fibrosis, and Inflammation in a Mouse Model of Pressure Overload.

Hao W, Cheng C, Chen H, Cheng T, Liu J, Chen J Biomedicines. 2025; 12(12.

PMID: 39767753 PMC: 11673818. DOI: 10.3390/biomedicines12122847.

Systolic Pulmonary Artery Pressure and Cardiovascular Biomarkers-New Non-Invasive Ways to Detect Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis Undergoing TAVR?.

Boxhammer E, Koller C, Paar V, Fejzic D, Rezar R, Reiter C Rev Cardiovasc Med. 2024; 23(7):224.

PMID: 39076911 PMC: 11266760. DOI: 10.31083/j.rcm2307224.

Hematopoietic Stem Cells as an Integrative Hub Linking Lifestyle to Cardiovascular Health.

Chen X, Liu C, Wang J, Du C Cells. 2024; 13(8.

PMID: 38667327 PMC: 11049205. DOI: 10.3390/cells13080712.

References

Weinberg E, Shimpo M, Hurwitz S, Tominaga S, Rouleau J, Lee R . Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107(5):721-6. DOI: 10.1161/01.cir.0000047274.66749.fe. View

Weinberg E . ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomark Med. 2010; 3(5):495-511. DOI: 10.2217/bmm.09.56. View

Higo S, Uematsu M, Yamagishi M, Ishibashi-Ueda H, Awata M, Morozumi T . Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ J. 2005; 69(10):1180-5. DOI: 10.1253/circj.69.1180. View

Zwaan L, Thijs A, Wagner C, Timmermans D . Does inappropriate selectivity in information use relate to diagnostic errors and patient harm? The diagnosis of patients with dyspnea. Soc Sci Med. 2013; 91:32-8. DOI: 10.1016/j.socscimed.2013.05.001. View

Brown A, Wu A, Clopton P, Robey J, Hollander J . ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann Emerg Med. 2007; 50(2):153-8, 158.e1. DOI: 10.1016/j.annemergmed.2007.02.015. View

Ahern R, Lozano R, Naghavi M, Foreman K, Gakidou E, Murray C . Improving the public health utility of global cardiovascular mortality data: the rise of ischemic heart disease. Popul Health Metr. 2011; 9:8. PMC: 3064613. DOI: 10.1186/1478-7954-9-8. View

Ciccone M, Scicchitano P, Zito A, Agati L, Gesualdo M, Mandolesi S . Correlation between coronary artery disease severity, left ventricular mass index and carotid intima media thickness, assessed by radio-frequency. Cardiovasc Ultrasound. 2011; 9:32. PMC: 3256115. DOI: 10.1186/1476-7120-9-32. View

Kohli P, Bonaca M, Kakkar R, Kudinova A, Scirica B, Sabatine M . Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2011; 58(1):257-66. PMC: 4277435. DOI: 10.1373/clinchem.2011.173369. View

Ho J, Chen W, Chen M, Larson M, McCabe E, Cheng S . Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest. 2013; 123(10):4208-18. PMC: 3784527. DOI: 10.1172/JCI67119. View

10.

Shah R, Chen-Tournoux A, Picard M, Van Kimmenade R, Januzzi J . Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009; 2(4):311-9. DOI: 10.1161/CIRCHEARTFAILURE.108.833707. View

11.

McMurray J, Adamopoulos S, Anker S, Auricchio A, Bohm M, Dickstein K . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the.... Eur Heart J. 2012; 33(14):1787-847. DOI: 10.1093/eurheartj/ehs104. View

12.

Bhardwaj A, Januzzi Jr J . ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn. 2010; 10(4):459-64. DOI: 10.1586/erm.10.25. View

13.

Sabatine M, Morrow D, Higgins L, Macgillivray C, Guo W, Bode C . Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117(15):1936-44. PMC: 4273564. DOI: 10.1161/CIRCULATIONAHA.107.728022. View

14.

Januzzi Jr J, Sakhuja R, ODonoghue M, Baggish A, Anwaruddin S, Chae C . Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006; 166(3):315-20. DOI: 10.1001/archinte.166.3.315. View

15.

Xanthakis V, Larson M, Wollert K, Aragam J, Cheng S, Ho J . Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc. 2013; 2(6):e000399. PMC: 3886765. DOI: 10.1161/JAHA.113.000399. View

16.

Ky B, French B, McCloskey K, Rame J, McIntosh E, Shahi P . High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2010; 4(2):180-7. PMC: 3163169. DOI: 10.1161/CIRCHEARTFAILURE.110.958223. View

17.

Sweet M, Leung B, Kang D, Sogaard M, Schulz K, Trajkovic V . A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol. 2001; 166(11):6633-9. DOI: 10.4049/jimmunol.166.11.6633. View

18.

Kaden J, Dempfle C, Sueselbeck T, Brueckmann M, Poerner T, Haghi D . Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology. 2003; 99(3):140-4. DOI: 10.1159/000070670. View

19.

Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B . Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008; 52(25):2166-74. PMC: 2637465. DOI: 10.1016/j.jacc.2008.09.027. View

20.

Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J . Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008; 14(9):732-8. DOI: 10.1016/j.cardfail.2008.06.415. View